ASH23 was made more memorable with the presenation of udpated acimtamig (AFM13) data & news on patient recruitment in our LuminICE-203 trial. Be sure to check out the details in the post below #acimtamig #AFM13
We are proud to see continued strong and durable responses for our lead innate cell engager (ICE®), acimtamig (AFM13) in a patient population that is left with few options, presented at the #ASH23 Annual Meeting today. The results presented by the principal investigator Yago Nieto, M.D., Ph.D., Professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center are unprecedented, especially for patients who failed prior chemotherapy and are double-refractory to brentuximab vedotin (BV) and checkpoint inhibitors (CPIs). Building on these results, we are well underway with our Phase 2 LuminICE-203 trial studying acimtamig in combination with AlloNK® (AB-101). We are enrolling and dosing patients in the first two cohorts and look forward to sharing data in the first half of 2024. We will host a webcast at 1:30 p.m. PST / 4:30 p.m. EST / 10:30 p.m. CET to review the data and provide a strategic update on acimtamig future development. Access additional details, including dial-in information in the press release at: https://lnkd.in/dFgSRtNQ
